Study identifier:D2452L00010
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A randomised, single blind, multicentre, 9-month, phase IV study, comparing treatment guided by clinical symptoms and signs and NT-proBNP vs treatment guided by clinical symptoms and signs alone, in patients with heart failure (HF) and left ventricular systolic dysfunction
heart failure
Phase 4
No
Captopril, Captopril, Enalapril, Enalapril, Lisinopril, Lisinopril, Ramipril, Ramipril, Trandolapril, Trandolapril, Bisoprolol, Bisoprolol, Carvedilol, Carvedilol, Metoprolol succinate, Metoprolol succinate, Candesartan, Candesartan, Valsartan, Valsartan, Eplerenone, Eplerenone, Spironolactone, Spironolactone, Diuretics, Diuretics, HF treatment according to Swedish guidelines, HF treatment according to Swedish guidelines
All
252
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Verified 01 Jun 2012 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Other: Guided by NT-proBNP Treatment guided by clinical symptoms and signs + NTproBNP | - |
Other: Not Guided by NT-proBNP Treatment guided by clinical symptoms and signs | - |